Peptide

Rusfertide

Also known as

MIMRYLO · PTG-300 · hepcidin mimetic · rusfertide PV

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	PTG-300, an iron-regulating peptide that mimics hepcidin and limits iron available for making red blood cells. The saved approval record names Mimrylo for adult polycythemia vera.
Why people discuss it	PV patients hope for fewer phlebotomies, or blood removals. Peptide-community approval comparisons concern a different job from weight loss or gym use.

Notes

An iron signal, rather than an appetite signal. Rusfertide, also called PTG-300, imitates hepcidin, a hormone that restricts iron availability for making red blood cells. Mimrylo is its U.S. brand, approved August 28, 2026 for excess red-cell production in adults with polycythemia vera (PV). FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder (Official context · Accessed 2026-09-30)

Rusfertide is an iron-regulating peptide discussed by people with polycythemia vera who want fewer blood draws and better daily function. Peptide communities use its approval as an example of medicine beyond weight loss. Patient reports differ, with fatigue remaining troublesome in one trial account.

Different questions in different communities. PV discussions concern hematocrit—the blood's red-cell fraction—and phlebotomy, meaning blood removal. TRT users ask about high counts; hemochromatosis discussions concern iron overload. Benefit in one condition does not establish benefit in another. Results of Phase 2 clinical trial of Rusfertide for PV (Secondhand community claim · Accessed 2026-09-30) · Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30) · Has anyone tried rusfertide (Mimrylo) off-label for HH? (Community discussion · Accessed 2026-09-30)

The peptide-versus-GLP comparison is about identity. A September peptide-community post uses the approval to illustrate disease-specific peptide medicines beyond GLP-1s. That develops the older card's comparison without turning it into a weight-loss benefit or a stack with semaglutide, tirzepatide or retatrutide. Rusfertide: The New FDA-Approved Peptide That Shows Where Peptide Medicine Is Heading (Community guide · Accessed 2026-09-30)

Source context — FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder: Official approval context, not community experience. VERIFY endpoint wording checked against label Table 5 rather than interpreting news-release shorthand as full-period efficacy.

Source context — Results of Phase 2 clinical trial of Rusfertide for PV: Trial-news interpretation and optimism, not a participant log; deleted comments cannot supply missing experiences. Same author as older recruiting post, not independent corroboration.

Source context — Rusfertide: Has anyone heard of this?: One claimed PV participant with later replies; separate unsourced dose comment. Identity, diagnoses and laboratory results unverified. Participant comment dates rendered relatively and cache-sensitive; no precise dates assigned.

Source context — Has anyone tried rusfertide (Mimrylo) off-label for HH?: Contemporaneous request for experience, not an established treatment log. Commenters circulate trial figures from different populations; no inferred prevalence, price, approval schedule or individual prescription guidance retained.

Source context — Rusfertide: The New FDA-Approved Peptide That Shows Where Peptide Medicine Is Heading: User-created explanatory approval essay; commercial affiliation not established, no first-person use. Clinical facts are checked separately, not counted as independent community outcomes.

What people notice

Positive trial-participant account	One participant reported hematocrit at or below 45%, no further phlebotomies, restored iron levels and less itching. Later updates are the same person's history.
Persistent fatigue	A different PV commenter reported severe fatigue persisting through several treatments, including a rusfertide trial. The account does not establish worsened fatigue or failed blood-count control.

Notes

One positive participant account has a continuing story. ConfusionChemical457 reports hematocrit at 45% or below, no further phlebotomies, restored iron levels and less itching. A later reply says platelets fell from above 1,100 to below 800 after added treatment. This remains one person's history, not independent corroboration. Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30)

Better energy remains a hope, not a universal experience. A PV commenter, mbcoyote, reported severe fatigue that persisted through several treatments, including a rusfertide trial. The account does not say rusfertide worsened fatigue or failed to control blood counts; it says the hoped-for fatigue relief did not occur. Fatigue before PV diagnosis (Personal report · Accessed 2026-09-30)

Persistent fatigue challenges the simple better-blood-equals-better-feeling story. Mbcoyote's account sits alongside the positive report because the outcomes differ. Their severe fatigue continued after multiple therapies; missing trial dose and blood results prevent attributing the whole illness course to rusfertide. It is useful evidence of a disappointing personal experience. Fatigue before PV diagnosis (Personal report · Accessed 2026-09-30)

Source context — Fatigue before PV diagnosis: Unverified retrospective account across several therapies; trial dose, assignment and objective results absent. Other commenters' phlebotomy experiences are not rusfertide outcomes.

Doses people talk about

Unsourced forum amount	1 mg every two days is repeated by a testosterone commenter without personal use, route, results or a supporting source. It is not an established range.
Participant frequency	A monitored PV trial participant reports weekly injections without stating milligrams.
Clinical label quantities	The saved label starts at 19 mg under the skin weekly, adjusted within 9.5–108 mg weekly. These medical label quantities are separate from community protocols.

Notes

1 mg every two days is an unverified forum claim. A testosterone commenter repeats this amount without reporting use, results, route or a supporting source. It is not an established community range. Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30)

A PV participant reports weekly injections; milligrams are unstated. This is a monitored trial account. Its frequency does not validate the separate every-two-days claim. Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30)

Clinical dosing has a different origin. The label starts at 19 mg under the skin weekly; the adjusted weekly total is 9.5–108 mg. Higher totals may require separate injections. These are clinical label quantities, not community protocols. MIMRYLO (rusfertide) prescribing information, revised August 2026 (Official context · Accessed 2026-09-30)

Source context — MIMRYLO (rusfertide) prescribing information, revised August 2026: Clinical label; human half-life in healthy participants after specified formulation/dose, fetal warning from animals. Not a DIY protocol, interaction assurance or source of community quick answers. Same clinical source family as FDA release for conservative word accounting.

Half-life, onset & duration

Felt onset	The patient accounts do not establish hours or days to first benefit. Blood-test changes and feeling more energetic are separate outcomes.
Felt duration	No single-dose or post-stop symptom-benefit window is recorded. One participant's injection-site soreness lasted a few hours.
Half-life	28.6 hours, with a standard deviation of 11.3 hours, in the saved label after 19 mg under the skin in healthy participants. This is measured exposure, not benefit duration.

Notes

No dependable hours-or-days onset from these reports. The fatigue account describes a treatment history without a time to first benefit. Trial-news enthusiasm also supplies no personal onset clock. Blood-test changes and feeling more energetic are separate outcomes. Fatigue before PV diagnosis (Personal report · Accessed 2026-09-30) · Results of Phase 2 clinical trial of Rusfertide for PV (Secondhand community claim · Accessed 2026-09-30)

A single-dose benefit window is unknown here. These discussions do not establish how long symptom relief lasts after one administration or stopping. A long treatment history answers a different question.

Blood-count control does not settle platelet problems. The participant later needed hydroxyurea for high platelets and described injection-site soreness lasting a few hours. Their favorable account includes these burdens. Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30)

Formal human half-life: 28.6 hours, with a standard deviation of 11.3 hours. This label measurement follows 19 mg under the skin in healthy participants. It measures blood-level decline, not a personal benefit window. MIMRYLO (rusfertide) prescribing information, revised August 2026 (Official context · Accessed 2026-09-30)

Cycles people discuss

Ongoing medical treatment	One participant dates weekly trial injections to November 2, 2023, without a break or repeat calendar. No gym cycle is reported.
Trial response window	VERIFY's weeks 20–32 measured eligibility for phlebotomy. That study window is neither an onset promise nor a cycle length.

Notes

Ongoing trial treatment, with no reported gym cycle. The participant dates weekly injections to November 2, 2023, without a planned break or repeat calendar. Rusfertide: Has anyone heard of this? (Community discussion · Accessed 2026-09-30)

VERIFY's response window was weeks 20–32. In this PV trial, 76.9% versus 32.9% on placebo met the definition of no phlebotomy eligibility during that window. It is neither a cycle length nor an onset promise. MIMRYLO (rusfertide) prescribing information, revised August 2026 (Official context · Accessed 2026-09-30)

Stacks

Hydroxyurea in medical care	The positive participant later required hydroxyurea for high platelets. This is continuing PV care, not a gym combination.
GLP-1 comparisons	Approval discussion compares peptide medicines with GLP-1 drugs; it does not describe a semaglutide, tirzepatide or retatrutide combination.

Notes

Watch for

Counts and injection reactions	Saved labeling warns about increased platelets, anemia and injection reactions. Blood-count control did not eliminate platelet problems in the positive account.
Pregnancy and breastfeeding	The saved label's fetal-harm warning comes from animal studies; breastfeeding is not recommended there.
Other conditions and product identity	TRT-related high counts and iron overload are different questions from PV. Speculation or a product listing does not establish benefit, identity or compatibility.

Notes

Label cautions extend beyond a sore injection site. Mimrylo labeling warns about increased platelets, anemia and injection reactions. Its fetal-harm warning comes from animal studies; breastfeeding is not recommended. These are medical cautions, not anecdotal prevalence estimates. MIMRYLO (rusfertide) prescribing information, revised August 2026 (Official context · Accessed 2026-09-30)

TRT and iron-overload speculation need their own evidence. A current hemochromatosis thread debates anemia and points out that PV adverse-event numbers describe a different population. Neither speculative use nor a product listing verifies benefit, identity or compatibility with other compounds. Long-term personal outcomes remain uncertain. Has anyone tried rusfertide (Mimrylo) off-label for HH? (Community discussion · Accessed 2026-09-30)

Full notes

What rusfertide actually does

An iron signal, rather than an appetite signal. Rusfertide, also called PTG-300, imitates hepcidin, a hormone that restricts iron availability for making red blood cells. Mimrylo is its U.S. brand, approved August 28, 2026 for excess red-cell production in adults with polycythemia vera (PV). Official context
Different questions in different communities. PV discussions concern hematocrit—the blood's red-cell fraction—and phlebotomy, meaning blood removal. TRT users ask about high counts; hemochromatosis discussions concern iron overload. Benefit in one condition does not establish benefit in another. Reddit r/MPN Reddit r/Testosterone Reddit r/Hemochromatosis

What people hope will improve

Less life organized around blood draws. PV forum interest centers on avoiding frequent phlebotomies. A Mayo Connect conversation shows why: a patient described short-lived relief followed by returning symptoms. That account concerns phlebotomy, not rusfertide, but explains the appeal of steadier control. Mayo Clinic Connect Reddit r/MPN
Better energy remains a hope, not a universal experience. A PV commenter, mbcoyote, reported severe fatigue that persisted through several treatments, including a rusfertide trial. The account does not say rusfertide worsened fatigue or failed to control blood counts; it says the hoped-for fatigue relief did not occur. Personal report

Doses people discuss

1 mg every two days is an unverified forum claim. A testosterone commenter repeats this amount without reporting use, results, route or a supporting source. It is not an established community range. Reddit r/Testosterone
A PV participant reports weekly injections; milligrams are unstated. This is a monitored trial account. Its frequency does not validate the separate every-two-days claim. Reddit r/Testosterone

Half-life

No measured community half-life in these accounts. The patient discussions describe treatment experiences and trial news, not how quickly the body clears the peptide. A formal human measurement appears separately below. Reddit r/MPN Community

Onset: when a change is noticed

No dependable hours-or-days onset from these reports. The fatigue account describes a treatment history without a time to first benefit. Trial-news enthusiasm also supplies no personal onset clock. Blood-test changes and feeling more energetic are separate outcomes. Personal report Reddit r/MPN

Duration: how long a change lasts

A single-dose benefit window is unknown here. These discussions do not establish how long symptom relief lasts after one administration or stopping. A long treatment history answers a different question. Community

Cycles and time off

Ongoing trial treatment, with no reported gym cycle. The participant dates weekly injections to November 2, 2023, without a planned break or repeat calendar. Reddit r/Testosterone Community

What deserves attention

Blood-count control does not settle platelet problems. The participant later needed hydroxyurea for high platelets and described injection-site soreness lasting a few hours. Their favorable account includes these burdens. Reddit r/Testosterone
Label cautions extend beyond a sore injection site. Mimrylo labeling warns about increased platelets, anemia and injection reactions. Its fetal-harm warning comes from animal studies; breastfeeding is not recommended. These are medical cautions, not anecdotal prevalence estimates. Official context
TRT and iron-overload speculation need their own evidence. A current hemochromatosis thread debates anemia and points out that PV adverse-event numbers describe a different population. Neither speculative use nor a product listing verifies benefit, identity or compatibility with other compounds. Long-term personal outcomes remain uncertain. Reddit r/Hemochromatosis Community

What the community accounts add

One positive participant account has a continuing story. ConfusionChemical457 reports hematocrit at 45% or below, no further phlebotomies, restored iron levels and less itching. A later reply says platelets fell from above 1,100 to below 800 after added treatment. This remains one person's history, not independent corroboration. Reddit r/Testosterone
Persistent fatigue challenges the simple better-blood-equals-better-feeling story. Mbcoyote's account sits alongside the positive report because the outcomes differ. Their severe fatigue continued after multiple therapies; missing trial dose and blood results prevent attributing the whole illness course to rusfertide. It is useful evidence of a disappointing personal experience. Personal report
Iron-overload discussions include disagreement about blood removal. A hemochromatosis poster welcomes hepcidin regulation, while another objects to describing phlebotomy as merely treating symptoms. Others worry about access and cost. These are expectations and arguments, not reports of taking rusfertide or proof it removes stored iron. Reddit r/Hemochromatosis
The peptide-versus-GLP comparison is about identity. A September peptide-community post uses the approval to illustrate disease-specific peptide medicines beyond GLP-1s. That develops the older card's comparison without turning it into a weight-loss benefit or a stack with semaglutide, tirzepatide or retatrutide. Community guide Community

Separately labeled clinical context

Clinical dosing has a different origin. The label starts at 19 mg under the skin weekly; the adjusted weekly total is 9.5–108 mg. Higher totals may require separate injections. These are clinical label quantities, not community protocols. Official context
Formal human half-life: 28.6 hours, with a standard deviation of 11.3 hours. This label measurement follows 19 mg under the skin in healthy participants. It measures blood-level decline, not a personal benefit window. Official context
VERIFY's response window was weeks 20–32. In this PV trial, 76.9% versus 32.9% on placebo met the definition of no phlebotomy eligibility during that window. It is neither a cycle length nor an onset promise. Official context